Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mortality from cardiovascular disease in women with breast cancer - a nationwide registry study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of human papillomavirus in sinonasal cancer-a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Reply to Letter to the Editor regarding "Elective neck dissection and its extent in Salivary gland cancers: A Dilemma"

    Research output: Contribution to journalLetterResearchpeer-review

  3. Prognostic scoring models in parotid gland carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.
Original languageEnglish
JournalActa oncologica
Volume27
Issue number5
Pages (from-to)521-5
Number of pages5
ISSN0284-186X
Publication statusPublished - 1988

    Research areas

  • Administration, Oral, Adult, Aged, Drug Evaluation, Female, Humans, Idarubicin, Male, Middle Aged, Neoplasms

ID: 43046184